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Washington, DCOne of the major dilemmas facing physicians is what diagnostic and therapeutic approaches should be
recommended to those stable coronary artery disease patients whose symptoms are adequately
controlled on medical therapy. This study sought to assess the evidence-based data relating to whether:
1) all patients with signiﬁcant coronary lesions (i.e., ischemia-producing) should undergo percutaneous
coronary intervention (PCI); 2) the best therapeutic approach is optimal medical therapy; or 3) PCI should
be performed, but only in certain subsets of patients. We reviewed all recent meta-analyses of prospective
randomized trials that compared the outcomes of medical therapy and PCI in stable, symptomatically
controlled, coronary artery disease patients. To provide greater insights to the clinician, we then analyzed,
in depth, 3 comprehensive and widely quoted randomized trials. Review of recently published (2012)
meta-analyses, and the detailed analyses of 3 widely quoted individual studies, indicate no difference
exists between PCI and medical therapy in nonfatal MI or in all-cause or cardiovascular mortality. Thus,
clinical equipoise exists: in other words, there is no evidence-based justiﬁcation for adopting 1 therapeutic
strategy over the other. Therefore, it is not inappropriate, until additional evidence emerges, for the
responsible, experiencedphysician toweigh several sources of information in formulatinga recommendation
to the patient, even though deﬁnitive evidence-based data are not as yet available. Such sources
may include assessment of the individual patient’s clinical presentation, assessment of the severity
of ischemia, and the patient’s precise coronary anatomy. Critical for more-reliable decision making
will be future development of accurate measures of the individual patient’s risk of MI and/or death,
whether by biomarker, imaging, or ischemia assessments. (J Am Coll Cardiol Intv 2013;6:993–8)
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for the care of patients with stable coronary artery
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tion (PCI)? Or does evidence-based data indicate
that the best therapeutic approach to such patients is
ensuring they are on optimal medical therapy
(OMT)? Or should PCI be performed, but only in
certain subsets of patients? This paper discusses the
complex issues involved in formulating a rational
response to these questions given, as will become
clear, that there are as yet no deﬁnitive answers.
Two fundamental pathophysiologic phenomena
account for most clinical manifestations of CAD:
1) progressive plaque build-up in epicardial arteries,
causing luminal narrowingdultimately limiting the
capacity to augment blood ﬂow response to
increases in myocardial demands, thereby causing
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994myocardial ischemia and thus angina; and 2) plaque rupture
causing intraluminal thrombus that occludes the vessel
lumen with consequent cessation of myocardial ﬂowd
resulting in the most devastating consequences of CAD:
myocardial infarction (MI) and sudden death. Although
these 2 pathophysiologic processes are related, they also have
unique aspects, an understanding of which would help the
physician choose the most appropriate therapeutic strategy
for a given patient.
Although atherosclerosis is the background process neces-
sary for plaque rupture to occur, it is not a sufﬁcient cause in
itself. Thus, many individuals with atherosclerosis, including
those experiencing myocardial ischemia, live into the late
decades of life without ever experiencing plaque rupture.
Others have MI early in their course, often without ﬁrst
experiencing reversible ischemic symptoms, that is,
angina. With the demonstration that distinct genetic differ-
ences mark patients with stable CAD versus those prone to
plaque rupture (1), it is likely that different pathways must beAbbreviations
and Acronyms
CABG = coronary artery
bypass graft
CAD = coronary artery
disease
FFR = fractional ﬂow reserve
MI = myocardial infarction
OMT = optimal medical
therapy
PCI = percutaneous coronary
intervention
VH-IVUS = virtual histologyactivated for a stable plaque to
become vulnerable to rupture.
Adding to the decision-making
complexities is the critically
important observation that it is
not necessary for an atheroscle-
rotic plaque to be signiﬁcantly
stenotic for rupture to occur (2–6).
Deﬁnitive evidenced-based
data demonstrates that PCI per-
formed in the setting of acute MI
reduces death and subsequent MI
(7). Our paper, however, focuses
solely on the patient with symp-
tomatically controlled stableCAD and explores 2 major issues. First, does PCI reduce the
incidence ofMI and/or death, or is any derived beneﬁt limited
to relief of symptoms? This distinction in outcome deﬁnition
is critical as if there is no penalty for delaying PCI until
signiﬁcantly limiting symptoms develop, then the case can be
made for delaying intervention, thereby avoiding the, albeit
small, risks posed by PCI. Second, if there is no clear beneﬁt of
PCI on the incidence of MI and/or death, is it justiﬁable for
the responsible physician, when formulating a therapeutic
recommendation to the patient, to consider information for
which deﬁnitive evidence-based data are not as yet available?
Simple answers are not forthcoming. However, we believe
it is important to understand the unresolved issues and
appreciate how decisions will have to be made in the absence
of deﬁnitive evidence.
Evidence From Recent Trials
There have been, to the best of our knowledge, 4 recent (2012
to 2013) meta-analyses that reviewed all available trials of
intravascular ultrasoundpatients with stable CAD in which patients were randomized
to medical therapy versus PCI, with the express intent of
determining whether PCI, when added to medical therapy,
improves outcomes versus medical therapy alone (8–11).
Each meta-analysis reviewed 8 to 12 randomized trials,
and there was overlap in the trials analyzed. The uniform
conclusion of each of the meta-analyses was that there
was no difference in incident MI or death between the 2
therapeutic approaches (Table 1).
We decided that to further enhance the insights available
to the clinician, we would, in addition to presenting the
conclusions of these meta-analyses, critically review in
depth 3 of the comprehensive and widely quoted ran-
domized trials: 1) the COURAGE (Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evalua-
tion) trial (12); 2) the FAME 2 (Fractional Flow Reserve
Versus Angiography for Multivessel Evaluation trial) (13);
and 3) the BARI 2D (Bypass Angioplasty Revasculariza-
tion Investigation 2 Diabetes) trial (14).
The COURAGE trial (12), published in 2007, showed
that symptoms improved more in patients with stable CAD
treated with PCI plus OMT versus OMT alone. However,
there was no difference between the 2 treatment groups in
the incidence of MI or death. The conclusions emerging
from these data were as follows: 1) PCI is justiﬁed if a patient
with stable CAD has symptoms sufﬁciently severe to com-
promise the quality of his/her life; and 2) it is not justiﬁed,
however, in such patients lacking limiting symptoms.
An important design component of the COURAGE trial
was that all candidates for recruitment had to undergo
coronary angiography, and it is likely that some patients were
excluded from the study because the responsible physician
decided that the patient’s anatomy posed an unacceptably
high risk without revascularization. Such decisions would have
excluded a subgroup of patients that might possibly have
beneﬁted from the revascularization procedure. As a corollary,
the COURAGE trial cannot be viewed as addressing the best
approach to diagnosis and treatment of stable CAD patients,
but rather as one testing relative treatment efﬁcacy on a highly
selected group of patientsdthe group remaining once coronary
angiography is performed and patients were eliminated from
study entry consequent to those results.
Despite this, the question can still be raised: Was there
a subgroup of patients in the COURAGE trial at high risk
of acute MI or death that actually beneﬁtted from revascu-
larization therapydan effect masked by the total cohort
analysis? This issue is not unique to the COURAGE trial, as
virtually all large clinical trials have heterogeneous patient
populations such that certain subgroups might respond
differently from the majority of study patients. And, prac-
tically speaking, it is virtually impossible to prospectively
identify all possible subgroups.
The COURAGE investigators recognized this and
sought to determine whether the development of inducible
Table 1. Meta-Analyses Assessing Impact of PCI Versus OMT on Incident MI and Death in Symptomatically
Controlled, Stable CAD Patients
First Author (Ref. #). Publication, year
Number of Trials
Analyzed Conclusions
Bangalore, et al. (8) Circulation, 2013 12 “PCI versus OMT for all-cause mortality and
cardiovascular mortality . . . not statistically
signiﬁcant.”
Thomas, et al. (9) Can J Cardiol, 2013 10 “We did not detect differences between
PCI vs. medical therapy for all-cause mortality,
CV mortality.”
Pursnani, et al. (10) Circ Cardiovasc Interv, 2012 12 “PCI, vs. OMT, did not reduce risk of mortality,
CV death, nonfatal MI, or revascularization.”
Stergiopoulos, et al. (11) Arch Intern Med, 2012 8 “Initial stent implantation . . . shows no . . .
beneﬁt vs. initial medical therapy for
prevention of death, nonfatal MI, unplanned
revascularization, or angina.”
CAD ¼ coronary artery disease; CV ¼ cardiovascular; MI ¼ myocardial infarction; OMT ¼ optimal medical therapy; PCI ¼ percutaneous coronary
intervention.
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995ischemia could identify such a subgroup. They reported, in
a retrospective data analysis published in 2008 (15), that
PCI more effectively reduced ischemia than OMT alone did
and that ischemia improvement was associated with a trend
to decreased events (death or nonfatal MI). Unfortunately,
a more recent retrospective analysis of the COURAGE trial,
examining the relationship between baseline stress-induced
myocardial ischemia and clinical outcomes based on
randomized treatment assignment (16), found that as a
result of programing errors, the 2008 results “incorrectly
reported a signiﬁcant probability value with regard to
worsening survival for OMT patients as compared with
PCI þ OMT for those with moderate to severe ischemia.”
In the updated analysis, patients were divided into those
with no to mild (<3 ischemic segments) and moderate
to severe ischemia (3 ischemic segments). The primary
endpoint, death or MI, was similar in the OMT alone and
the PCI þ OMT treatment groups for all severities of
ischemia. Thus, the COURAGE trial does not demonstrate
that PCI performed in stable CAD patients with ischemia
decreases death or nonfatal MI.
Nonetheless, retrospective reviews of registry data (17)
support speculation that interventions improving is-
chemia should reduce cardiac events. Consequently, the
COURAGE investigators have initiated such a trialdthe
ISCHEMIA (International Study of Comparative Health
Effectiveness with Medical and Invasive Approaches)
trial (NCT01471522). This study randomizes stable CAD
patients with moderate-to-severe left ventricular ischemia
into 2 treatment subgroups: PCI þ OMT versus OMT
alone. The study may begin to resolve the conundrum of
whether PCI should be performed in patients with inducible
ischemia even if the severity of ischemic symptoms would
not in itself warrant PCI. However, close to 90% of patients
with stable CAD with no prior MI have ischemia involving
<10% of the left ventricular myocardium, a value that wouldexclude them from entry into the ISCHEMIA trial (17).
Thus, the results of the ISCHEMIA trial will not apply to
the great majority of stable CAD patients who have lesser
degrees of ischemia and who routinely form the basis for
contemporary revascularization.
Although results from the ISCHEMIA trial are years away,
another trial has just been published that also tested the
concept that PCI performed in patients with ischemia will
result in fewer cardiac events thanwill occur in patients treated
withOMT alone. The FAME2 trial (13) used fractional ﬂow
reserve (FFR), an index obtained by measuring pressures
proximal and distal to the stenosis and then dividing the distal
by the proximal pressure; the more severe the stenosis, the
greater the pressure drop across it and hence the lower the
FFR. FFR 0.80 is now commonly taken as functional
evidence that lesions having such values are severe enough to
produce ischemia and, therefore, are justiﬁed PCI targets.
The results of the FAME 2 trial validated the study
hypothesis. The primary endpoint was a composite of death,
MI, or urgent revascularization. Revascularization was de-
ﬁned as urgent when a patient was admitted to the hospital
with persistent or increasing chest pain (with or without ST-
segment or T-wave changes or elevated biomarker levels),
and revascularization was performed during the same
hospitalization.
Of 888 patients, 70 (8.4%) developed at least 1 primary
endpoint event: 4.3% in the PCI group and 12.7% in the
medical therapy group (p < 0.001). Most critically, however,
the sole driving force responsible for the differences between
the PCI þ OMT alone groups was the rate of urgent
revascularization (11% in the medical therapy group vs.
1.6% in the PCI group; p < 0.001). There were no differ-
ences between the 2 treatment groups in the incidence of
MI and/or death. Although urgent revascularization is an
important clinical endpoint, the fact remains that the
increased need for urgent revascularization during follow-up
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should be noted, however, that the incidence of MI and
death was small (about 4% over the ﬁrst year), suggesting
that the trial probably did not have the statistical power to
deﬁnitively test the effects of PCI on these endpoints.
Another issue arises because of study design. Patients and
physicians were obviously not blinded as to whether
a patient was randomized to PCI therapy. Therefore, it is
likely that the responsible physician of a patient not assigned
to the PCI group would more likely interpret any symp-
tomatic change as needing urgent revascularization than if
the patient had the prior “beneﬁt” of PCI therapy.
Because the FAME 2 trial conﬁrmed its primary
composite endpoint, it could be concluded that PCI is
indicated in all patients who have stenoses with FFR 0.80.
However, an alternative therapeutic strategy can be consid-
ered: namely, deferring PCI for patients who have lesions
with an FFR 0.80 until they need “urgent” revasculariza-
tion. The rationale for this approach is that, ﬁrst, in the
FAME 2 trial, deferring PCI did not increase the rate of MI
or death and, second, it spares from a seemingly unnecessary
intervention the approximately 90% of patients who, despite
having an FFR of 0.80, remain symptomatically stable and
do not require urgent revascularization. Deferring PCI
would also eliminate the small but deﬁnite risks incurred by
PCI (18).
Such an approach is also supported by the fact that
despite many trials, including the FAME 2 trial, PCI has
not been shown to reduce the incidence of MI or death
(14,19–21), a ﬁnding also reported in the meta-analyses
noted earlier (8–11). One of the major trials testing this
question prospectively was the BARI 2D trial (14). This was
a complex randomized study in which diabetic patients with
stable CAD were ﬁrst separated, based on clinical consid-
erations, into a CABG stratum and into a PCI stratum.
Within each stratum, patients were randomized into
a medical therapy group versus the particular revasculari-
zation strategy group. Primary endpoints were rate of death
and a composite of death, MI, or stroke. Patients in the
coronary artery bypass graft (CABG) stratum undergoing
revascularization had signiﬁcantly fewer major cardiovas-
cular events over the 5-year follow-up than did patients in
the CABG stratum assigned to medical therapy (p ¼ 0.01).
Although there was no difference in death rate, in the
CABG stratum nonfatal MI occurred in 7.4% of patients
undergoing CABG versus 14.6% in patients assigned to
medical therapy. In contrast, the rates of cardiovascular
events among patients in the PCI stratum assigned to
revascularization versus medical therapy did not differ.
A possible explanation for why PCI does not appear to
protect against future MI derives from studies in which
coronary angiography was performed prior to a subsequent
cardiovascular eventdmost prominently, the PROSPECT
(Providing Regional Observations to Study Predictors ofEvents in the Coronary Tree) trial (6,22). Although the
PROSPECT trial involved patients who presented with an
acute coronary syndrome, we discuss it here because all
patients underwent extensive 3-vessel coronary imaging
studies after PCI of the culprit lesions (i.e., those lesions
believed to have been responsible for the index event), and
were then followed, thereby providing insight regarding the
relation between speciﬁc lesion characteristics and subse-
quent events.
On follow-up, about one-half of the events that occurred
were due to disease progression in a vessel judged at index
catheterization not to be the culprit lesion; moreover, over
one-half of these new culprit lesions had produced <70%
obstruction at initial catheterization. Thus, many cardio-
vascular events occur consequent to progression or rupture of
a plaque that at initial catheterization did not cause signif-
icant (>70%) obstruction. That angiographically nonsig-
niﬁcant stenoses could rupture and lead to MI was ﬁrst
reported in 1988 by Ambrose et al. (2) and by Little et al. (3)
and subsequently reviewed and conceptualized (4,5). These
investigators emphasized that plaques producing severe
stenosis rupture more frequently than do plaques producing
mild stenosis; however, because less obstructive plaques far
outnumber severely obstructive ones, a high percentage of
plaque rupture derives from plaques that produce mild
obstruction.
Additionally, it is instructive to consider the predictive
value of measures of the ischemia-inducing potential of
a lesion, like FFR. That is, when the interventionist ﬁnds an
artery with a lesion that has an FFR 0.80, how often will
such a lesion lead to an event? In the FAME 2 trial (13), there
were 625 lesions in the control group with an FFR 0.80;
however, the total number of patients dying or experiencing
anMI over 1 year was only 17 of 441. In other words, only 17
of 625 (3%) plaques that functionally were capable of
producing ischemia actually went on to clinically evident
rupture. Thus, the predictive accuracy of an FFR0.80dthat
is, its ability to predict future plaque rupturedis extremely
low.
These ﬁndings of the FAME 2 (13) and PROSPECT
trials (6,22), as well as the studies demonstrating that plaque
rupture commonly occurs in lesions producing mild
obstruction (2–6,22), emphasize a critically important con-
ceptdthat anatomic or functional severity of a stenosis, or
lack of severity, is not a good way to predict risk of plaque
rupture and, therefore, MI and death. They also emphasize,
more generically, that the risk of future plaque rupture
(as distinct from plaque progression leading not to MI but to
progression of symptoms) is very low, even in patients pre-
senting with acute coronary syndromes. Finally, the converse
is also true: a subgroup of patients do not seem to experience
angina even in the presence of severe stenosis or even MI
(4,5). Thus, severity of symptoms cannot be used as
a surrogate for risk of MI or death.
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997The Persisting Dilemma
If no more than 5% of patients studied in the catheterization
laboratory for either acute coronary syndromes or stable CAD
go on to develop over the next few years a life-threatening or
myocardial injuring event, that is, plaque rupture, how can
a therapeutic intervention, such as PCI, be justiﬁed as a wise
therapeutic strategy if the large majority of patients in whom
it will be performed do not develop the clinical syndrome
for which the interventional procedure was intended? Espe-
cially if the intervention carries with it low, but nonetheless
signiﬁcant, risks? The dilemma becomes even greater when
the fact that rupture frequently occurs from a plaque pro-
ducing mild obstruction (and therefore would not have been
the lesion targeted for PCI) is factored into the equation.
This formulation of the therapeutic dilemma indicates that
there is a compelling need to shift primary focus from the
anatomic or functional severity of a plaque to its vulnerability
to rupture. Basically, the attempts to identify patients at high
risk for developing plaque rupture involves 2 approaches.
The ﬁrst involves invasive technologies to deﬁne the
characteristics of plaques that are associated with a propen-
sity to rupture. Initial excitement about the capacity of
virtual histology intravascular ultrasound (VH-IVUS) to
identify vulnerable plaques has moderated, given the results
of the PROSPECT trial (16). In this study, 595 thin-cap
ﬁbroatheromas were identiﬁed by VH-IVUS; only 26 were
sites of recurrent events at a median follow-up of 3.4 years
(estimated cumulative event rate ¼ 4.3%, or 1.3%/year). The
trial also evaluated the predictive value of ultrasound-
determined plaque burden of at least 70% (event rate 9.6%)
and a minimal luminal area of 4.0 mm2 or less (event rate
5.3%). When the data from all 3 modalities were present in
a patient, the event rate rose to 18.2% over the 3.4 years;
importantly, these events were mainly driven by rehospitali-
zation due to unstable or progressive angina, as death from
cardiac causes, cardiac arrest, or MI occurred with a cumu-
lative 3-year rate of only 4.9%. Optical coherence tomog-
raphy, with its high-resolution capacity, can identify thin-cap
ﬁbroatheromas, and the Infraredx catheter (Burlington,
Massachusetts), with its capacity to identify lipid in plaques,
are both promising modalities that might help identify pla-
ques that are vulnerable to rupture. However, there are
presently no natural history studies comparable to the data we
have with VH-IVUS and FFR. Thus, none of the invasive
imaging technologies currently available have as yet been
shown to provide actionable clinical information about
which plaques will rupture to guide therapeutic decisions.
The second approach to identify vulnerable plaque is the
use of circulating biomarkers that can identify the “vulnerable
patient.” Although many different biomarkers have been
shown to identify stable CADpatients with increased risk, the
absolute level of near-term risk is relatively low. However,
a recent publication, analyzing for 3 biomarkers, each of whichis involved in pathways associated with the development
of vulnerable plaque, demonstrated that when 3 of the
biomarkers are abnormal in patients with signiﬁcant CAD,
the risk of near-term MI or death is 18% (23). If these results
are conﬁrmed, such information could be used to deﬁnewhich
patients with presumably stable CAD should be catheterized
to determine whether high-grade proximal stenoses are
present. As discussed previously, although such lesions by
themselves do not provide sufﬁcient reason for revasculari-
zation (with the exception of signiﬁcant left main coronary
stenosis or, perhaps, extensive 3-vessel disease [24]), the
presence of a high-risk biomarker proﬁle might well tilt the
balance in favor of more aggressive therapeutic approaches.
Given that clinical equipoise exists (25)dthat is, no deﬁn-
itive evidence exists proving the superiority of PCI versus
OMT in reducing the risk of MI and/or death in patients
with stable CADdit is not unreasonable to incorporate
into the decision-making process something commonly used
in the daily practice of medicinedthe judgment of the
individual, experienced clinician. In this regard, 1 salient fact
looms large when an individual patient is being studied in the
catheterization laboratorydenormous anatomic and clinical
variability exists from patient to patient: Does the lesion
appear complex? Are there poor or excellent collaterals to the
ischemic myocardium? Are there multiple coronary arteries
signiﬁcantly narrowed or only a single vessel? Although
“stable,” have the patient’s symptoms actually been somewhat
progressive? This variability of factors that may well inﬂuence
outcome strongly suggests that a conclusion of clinical equi-
poise applicable to a total cohort may not apply to subgroups
of patients or to individual patients.
The expert clinician, who frequently deals with this
individual variability, gradually builds an experience leading
to “clinical impressions”dthese are not to be found in
published databases and do not rise to the level of compel-
ling evidence. And whereas any decisions made that are
based on these impressions often prove to be wrong once the
evidence of deﬁnitive randomized trials emerges, until such
trials are completed, these judgments constitute an essential
component of providing our patients with the bestdalbeit
imperfectdavailable advice for therapeutic options.
Conclusions
It seems clear that in patients with a hemodynamically
signiﬁcant lesion and severe symptoms despite OMT,
symptom control is a perfectly legitimate basis for recom-
mending PCI (17). However, the conundrum arises in
patients whose symptoms are adequately controlled but
whose lesions are associated with ischemia (whether mild or
severe). These patients have, at least anatomically, lesions
that could be targeted by PCI. Rather than subjecting all
such patients to PCI, with its attendant risks, it might be
more reasonable to defer PCI until patients are in need of
Epstein et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 1 0 , 2 0 1 3
PCI Versus Medical Therapy in Stable CAD O C T O B E R 2 0 1 3 : 9 9 3 – 8
998revascularization based on their symptoms, because it does
not appear that a penalty is paid if such a strategy is pursued.
Thus, this “wait and see strategy,” as used for the medically
treated patients of the FAME 2 trial: 1) did not result in a
higher incidence of MI or death; 2) led to PCI being per-
formed only in that small subgroup of patients who needed
it during follow-up because of progression of symptoms;
and, conversely, 3) led to withholding PCI from the large
majority of patients who during follow-up remained clini-
cally stable and did not develop any clinical indications
warranting revascularization.
As discussed, however, the FAME 2 trial was prematurely
terminated and not adequately powered to deﬁnitively
determine that PCI does not reduce the incidence of MI or
death. Thus, as is often the case in medicine, decisions have
to be made in the absence of deﬁnitive data. Under these
circumstances, the physician’s only recourse is to analyze the
available information, come to what appear to be reasonable
conclusions, discuss in depth the issues with the patient, and
then, for physician and patient to make decisions that derive
from the best, albeit limited, available data. The place of PCI
in the management of many patients with stable CAD and
without limiting symptoms falls into this category. Whether
or not the speciﬁc decision made on the basis of careful
weighing of incomplete data results in the right decision will
be proven only by carrying out deﬁnitive studies.
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